China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC) Short Interest Update

Key Points

• Short interest in China SXT Pharmaceuticals fell sharply in June, dropping 37.4% to 45,019 shares as of June 30. That leaves the stock with just 0.1% of shares sold short and a days-to-cover ratio of 0.9 days.
• Analyst sentiment remains weak, with Weiss Ratings downgrading the stock from "sell (e)" to "sell (e+)" on July 10. MarketBeat data shows an overall average rating of "Sell."
• The company reported a small quarterly loss, posting EPS of -$0.07 on revenue of $0.26 million. The stock also trades far below its 200-day moving average, reflecting ongoing weakness.

China SXT Pharmaceuticals, Inc. (NASDAQ:SXTC - Get Free Report) was the recipient of a significant decline in short interest during the month of June. As of June 30th, there was short interest totaling 45,019 shares, a decline of 37.4% from the June 15th total of 71,896 shares. Based on an average daily volume of 50,754 shares, the days-to-cover ratio is currently 0.9 days. Currently, 0.1% of the company's shares are short sold.

Analysts Set New Price Targets

Separately, Weiss Ratings raised China SXT Pharmaceuticals from a "sell (e)" rating to a "sell (e+)" rating in a research note on Friday, July 10th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the stock presently has an average rating of "Sell".

China SXT Pharmaceuticals Stock Performance

Shares of NASDAQ SXTC opened at $2.54 on Friday. The firm's 50 day moving average price is $2.02 and its 200-day moving average price is $18.65. The company has a current ratio of 7.94, a quick ratio of 7.76 and a debt-to-equity ratio of 0.02. China SXT Pharmaceuticals has a 52-week low of $1.25 and a 52-week high of $1,046.98.

China SXT Pharmaceuticals (NASDAQ:SXTC - Get Free Report) last released its quarterly earnings data on Wednesday, July 1st. The company reported ($0.07) EPS for the quarter. The company had revenue of $0.26 million during the quarter.

Institutional Trading of China SXT Pharmaceuticals

Hedge funds and other institutional investors have recently modified their holdings of the company. XTX Topco Ltd bought a new stake in shares of China SXT Pharmaceuticals during the fourth quarter valued at approximately $36,000. Citadel Advisors LLC purchased a new stake in shares of China SXT Pharmaceuticals during the 3rd quarter valued at about $78,000. Finally, Virtu Financial LLC lifted its stake in shares of China SXT Pharmaceuticals by 107.5% in the 3rd quarter. Virtu Financial LLC now owns 28,983 shares of the company's stock valued at $46,000 after purchasing an additional 15,013 shares during the last quarter. 5.02% of the stock is owned by hedge funds and other institutional investors.

China SXT Pharmaceuticals Company Profile

China SXT Pharmaceuticals Inc NASDAQ: SXTC is a China-based biopharmaceutical company focused on the research, development, manufacturing and commercialization of peptide-based therapeutics. The company’s pipeline centers on novel treatments targeting oncology, endocrine and metabolic disorders. By leveraging proprietary peptide synthesis and formulation technologies, China SXT aims to advance next-generation biologics that address unmet medical needs in both domestic and international markets.

The company’s core product candidates include long-acting peptide hormones and peptide-drug conjugates designed to improve patient compliance and therapeutic efficacy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.